Instructions for Authors

Scope

Clinical Cancer Research, a journal of the American Association for Cancer Research, publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients.

Specific areas of interest include clinical and translational research in: molecular pharmacology and chemotherapy; drug sensitivity and resistance; tumor immunology and immunotherapy; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; pathology, markers, and prognostic indicators; growth factors, cytokines, and signal transduction; bone marrow transplantation; gene therapy; cancer endocrinology; cell adhesion, invasion, and metastasis; prevention of primary and recurrent cancer; differentiation and cell death; clinical genetics; and detection of minimal disease.

Editorial Policy

When a manuscript is received for consideration, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission. The signature of the corresponding author on the letter of submission signifies that these conditions have been fulfilled.

Journal policy requires that authors, reviewers, Associate Editors, and Senior Editors reveal in a letter to the Editor-in-Chief any relationships that they have that could be construed as causing a conflict of interest with regard to a manuscript under review. The letter should include a statement of any financial relationships with commercial companies involved with a product under study.

Upon acceptance, authors must transfer copyright to the American Association for Cancer Research, Inc., the copyright owner of the journal, prior to publication. Once an article is accepted for publication in Clinical Cancer Research, the information therein is embargoed from reporting by the media until the mail date of the issue in which the article appears.

The Editors endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving humans will have been performed in accordance with these principles. To obtain a copy of the Helsinki Declaration, please contact the World Medical Association, 28, Ave. des Alpes, F-01210, Ferney-Voltaire, France. For animal experimentation reported in the journal, it is expected that investigators will have observed the Interdisciplinary Principles and Guidelines for the Use of Animals in Research, Testing, and Education issued by the New York Academy of Sciences’ Ad Hoc Committee on Animal Research, a copy of which is available for $5.00 from the Marketing Department, New York Academy of Sciences, 2 East 63rd Street, New York, NY 10021-7289. All human and animal studies must have been approved by the investigator’s Institutional Review Board.

Review Process

The review process, expedited by fax transmission and overnight mail service, is conducted as rapidly as possible. Each submitted manuscript is reviewed by at least two experts in the field of investigation. If the authors are invited to submit a revised manuscript for an expedited further review, the revised version must be submitted within three months.

Manuscript Submission

Submit papers directly to one of the six Senior Editors, each of whom is responsible for a particular area of research. Senior Editors will conduct the review process with the expert assistance of the journal’s Associate Editors, will correspond with authors about their manuscripts, and will make editorial decisions regarding publication. Papers within the subject areas covered by the Editor-in-Chief, as well as manuscripts that do not pertain to any of the research areas listed, should be submitted to Dr. Mendelsohn. Research areas, mailing addresses, and telephone and fax numbers for the Editor-in-Chief and Senior Editors can be found at the end of these Instructions.

Submit four original sets (not photocopies) of figures along with four copies of the manuscript. If a manuscript is closely related to papers that are in press or have been submitted elsewhere, please provide copies of those papers with your submission. For both original and revised submissions, we cannot guarantee that manuscripts and illustrations will be returned to the author.

The letter of submission can suggest the Associate Editors who might serve as reviewers of the manuscript. In addition, we invite authors to provide the names, addresses, and telephone/fax numbers of other potential reviewers who are not current or recent collaborators or advisors in the area under investigation.

Advances in Brief will be reserved for concise, definitive reports of novel observations and discoveries that have unusual importance. A request for consideration for Advances in Brief should be included in the letter of submission. A Minireview is a brief analysis (typically 3-4 printed pages) of a focused, timely research topic, aimed at a multidisciplinary audience. Minireviews and Controversies in Clinical Cancer Research that are submitted or solicited will undergo editorial review. The Editors welcome Letters to the Editor, which will be published if they are determined to be appropriate.

Format

Manuscripts must be written succinctly in clear, grammatical English. Define abbreviations in an inclusive footnote to the text. Double-space on 8 1/2 x 11-inch paper. Dot-matrix printing is not acceptable. The format is as follows:

1. Title page, including title, authors and their institutions, research support, and address plus telephone/fax numbers of the corresponding author;
2. A running title of fewer than 50 characters;
3. Three to five key words that do not appear in the title;
4. Abstract, of not more than 250 words, stating briefly the objectives, methods, results, and conclusions of the study;
5. Text arranged in this order: Introduction, Methods, Results, Discussion, Acknowledgments, References;
6. Footnotes, on a page separate from the text. Designate footnotes consecutively with superscript Arabic numerals;
7. Tables, on pages separate from the text, with descriptive titles and legends that make the data understandable without reference to the text;
8. Figure legends, on pages separate from the text, with descriptive titles and explanations to make the data understandable without reference to the text. Define all symbols and include staining for halftones where applicable;

References

Include only those articles that have been published or are in press. Unpublished data or personal communications must be cited as footnotes to the text. Personal communications should be substantiated by a letter of permission. Number references in the order of their first mention in the text. Cite only the number assigned to the reference. References must be double-spaced.

SAMPLE REFERENCES:


Figures

Provide four original sets of figures (whether line-cut drawings or halftones). Each sorted set should be in a separate labeled envelope, for distribution to reviewers. A typed label placed on the reverse side of each figure should contain the first author's name, figure number, and an arrow indicating top of figure. Letters and numbers on figures should not be smaller than 6-point or larger than 12-point type. All figures will be published at a width of approximately 3 inches (8 cm) unless the author requests a greater width. Use overlays to indicate important areas of the photographs that must be reproduced with greater fidelity.

Authors are encouraged to submit color figures. The expense of reproducing color photographs must be offset partially by the author. In 1996, the cost of color reproduction charged to authors will be $975 per color figure. Submit color figures on flexible backing.

Proofs

Page proofs must be returned to the office of the American Association for Cancer Research within 24 hours of receipt. Return proofs by overnight mail. Proofs not received by the deadline will be published without the authors' corrections. Accepted manuscripts are regarded as final copy and should not be altered substantially in proof. Extensive alterations could cause publication delays, and authors will be charged for excessive alterations in proof.

Typesetting Manuscripts from Computer Disks

Clinical Cancer Research welcomes disks to expedite production of accepted manuscripts. If your article is accepted for publication, you will receive instructions regarding disk submission. It is the author's responsibility to ensure that the material on the disk matches the final accepted version of the manuscript.

Research Areas of the Editor-in-Chief and Senior Editors

John Mendelsohn, M.D.
Department of Educational Publishing Services--227
The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Boulevard
Houston, TX 77030
Telephone: 713-792-6014
Fax: 713-792-6016
E-mail: jmendelsohn@notes.mdacc.tmc.edu

Cell proliferation and death—preclinical, and clinical trials; radiation therapy, surgery, and subspecialty investigation

Waun Ki Hong, M.D.
Department of Thoracic/Head & Neck Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Box 80
1515 Holcombe Boulevard
Houston, TX 77030
Telephone: 713-792-6363
Fax: 713-796-8655
E-mail: waun_hong@isqm.mdadm.tmc.edu

Clinical trials targeted at specific malignancies; chemoprevention

Lance A. Liotta, M.D., Ph.D.
Laboratory of Pathology
National Cancer Institute
Building 10, Room 2A33
National Institutes of Health
10 Center Drive, MSC 1500
Bethesda, MD 20892-1500
Telephone: 301-496-3185
Fax: 301-402-0043
E-mail: lance@helix.nih.gov

Pathology, metastasis

David Sidransky, M.D.
Otolaryngology/Head & Neck Cancer Research
Johns Hopkins University
818 Ross Research Building
720 Rutland Avenue
Baltimore, MD 21205-2196
Telephone: 410-550-5153
Fax: 410-614-1411
E-mail: dsidrans@welchlink.welch.jhu.edu

Molecular pathogenesis, molecular correlates

Paul Sondel, M.D., Ph.D.
Departments of Pediatrics, Human Oncology, & Genetics
University of Wisconsin Clinical Science Center
K4/448
600 Highland Avenue
Madison, WI 53792
Telephone: 608-263-9069
Fax: 608-263-4226
E-mail: pmsondel@facstaff.wisc.edu

Immunotherapy and cytokines—preclinical, and clinical trials

David R. Spriggs, M.D.
Developmental Chemotherapy Service
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, NY 10021
Telephone: 212-639-2203
Fax: 212-717-3272
E-mail: dspriggs@pop.ski.mskcc.org

Preclinical pharmacology, pharmacological clinical trials

Jeffrey M. Trent, Ph.D.
Laboratory of Cancer Genetics
National Center for Human Genome Research
National Institutes of Health
Building 49, Room 4A22
49 Convent Drive, MSC 4470
Bethesda, MD 20892-4470
Telephone: 301-402-2023
Fax: 301-402-2040
E-mail: j Trent@nchgr.nih.gov

Genetics, cytogenetics

For more information, contact:
John Mendelsohn, M.D., Editor-in-Chief, Clinical Cancer Research, Department of Educational Publishing Services--227, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, Telephone 713-792-6014, Fax 713-792-6016 or:
BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society of over 11,000 laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting;
2. an advance copy of the Program and Proceedings of the American Association for Cancer Research that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
3. reduced registration rates at annual meetings;
4. priority notice of small, focussed meetings in the AACR’s exciting series of Special Conferences in Cancer Research;
5. substantially reduced registration rates for Special Conferences;
6. opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
7. receipt of AACR Newsletters and other important announcements;
8. early notification of and reduced rates for participation in the AACR Employment Register;
9. an up-to-date Membership Directory of over 11,000 member researchers in the cancer field;
10. the professional benefits of the AACR’s public education activities concerning funding for cancer research and press coverage of the latest research findings;
11. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators;
12. the facilitation of informal scientific exchange with leading researchers in the cancer field; and
13. many more ongoing benefits.

QUALIFICATIONS FOR MEMBERSHIP

Active membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If a candidate has conducted research in an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be submitted as qualifications for membership in lieu of peer-reviewed publications.

Corresponding membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those indicated above for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visiting scientists should apply for active membership and transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications for active or corresponding membership should apply for associate membership. Forms for associate membership are available from the AACR Office.

PROCEDURES FOR APPLICATION

There are three deadlines for the receipt of a membership application: January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all members. The same procedure is followed by the Special Memberships Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

<table>
<thead>
<tr>
<th>Receipt of Application</th>
<th>Notification of Candidate</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 1</td>
<td>March</td>
</tr>
<tr>
<td>May 1</td>
<td>July</td>
</tr>
<tr>
<td>September 1</td>
<td>November</td>
</tr>
</tbody>
</table>

A complete application consists of the following material:

1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate’s most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate’s achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical scientific standards. –OR– The nominator may supply the responses requested at the bottom of the application form in the section entitled “STATEMENT OF SUPPORT” (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above from a secondor who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). –OR– The secondor may supply the responses requested at the bottom of the application form in the section entitled “STATEMENT OF SUPPORT” (at least one copy of the form must be the signed original).
5. Reprints of each of the candidate’s publications on which the candidate appears as author. As noted above, evidence of patents developed by the candidate may be submitted in lieu of one or both of the publications. If submitting patents, supply patent number and year awarded.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
FAX: 215/440-9313
E-mail: aacr@aol.com

RESPONSIBILITIES OF MEMBERSHIP

Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues. In 1996 annual dues for active members are $160, $95 of which is designated for AACR journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rates will receive reimbursement of the unused portion of those subscriptions once their first year’s membership dues are paid in full.

Corresponding members are required to pay dues ($80 in 1996) and may, if they wish, subscribe to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at reduced member rates.

Applicants elected in March will be responsible for payment of that year’s dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Foti, Ph.D.
Executive Director
APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP

NAME OF CANDIDATE: ___________________________ DATE OF BIRTH: ____________

LAST FIRST M.I.

PRESENT POSITION/TITLE: ___________________________

INSTITUTIONAL AFFILIATION: ___________________________

INSTITUTIONAL ADDRESS: ___________________________

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER: ___________________________

E-MAIL NUMBER (CARRIER): ___________________________

FAX NUMBER: ___________________________

PRIMARY FIELD OF RESEARCH (Please check only one):

- Biochemistry and Biophysics
- Cellular Biology and Genetics
- Epidemiology
- Experimental Therapeutics
- Preclinical Pharmacology and Experimental Therapeutics
- Biostatistics
- Clinical Investigations
- Immunology
- Virology
- Carcinogenesis
- Endocrinology
- Molecular Biology and Genetics
- Other: ___________________________

(Please specify)

ACADEMIC DEGREES (Including where and when granted)

EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first)

PUBLICATIONS (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent number and year awarded.)

CANDIDATE NOMINATED BY*: ___________________________ (Please print)

CANDIDATE SECONDED BY*: ___________________________ (Please print)

CANDIDATE IS APPLYING FOR (Check one): ☐ ACTIVE ☐ CORRESPONDING MEMBERSHIP

STATEMENT OF SUPPORT

Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

How long has the candidate worked in the field of cancer research? _____ years

Will the candidate make a long-term contribution to cancer research? _____ Yes _____ No

Does the candidate’s research adhere to accepted ethical standards? _____ Yes _____ No

I therefore recommend this candidate for membership in the American Association for Cancer Research.

Signature of nominator* ___________________________ Date ___________________________

Signature of seconder* ___________________________ Date ___________________________

See Guidelines for Application on the reverse side of this form for further instructions.

*Both nominator and seconder must be active, corresponding, emeritus, or honorary members of the AACR.
QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confers full benefits of membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AACR also signs the abstract of the paper in support of the work. (In this instance, the member who cosigns the abstract does not lose his or her own sponsorship privilege.);
2. an advance copy of the scientific Program and (if one has been purchased by the associate member) the Proceedings of the American Association for Cancer Research that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
3. the privilege of registering for the annual meeting at the low associate member rate;
4. preferred access to the AACR Employment Register;
5. optional subscriptions to the Association’s high-quality journals Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at reduced member rates;
6. priority notification of events in the AACR’s series of special conferences on timely subjects in the field;
7. substantially reduced registration rates at special conferences;
8. the receipt of AACR newsletters, meeting announcements, and an up-to-date Membership Directory;
9. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators; and
10. the facilitation of informal scientific exchange with leading researchers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the AACR. Three completed copies of the form should be submitted: at least one of these copies must carry the original signatures of both the candidate and the nominator. The application form may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year’s dues payment must accompany the application. Dues are currently $35 for associate members residing in the Americas and $45 for residents of other countries. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the $35 or $45 dues payment to:

American Association for Cancer Research
Public Ledger Building, Suite 816
1501 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
FAX: 215/440-9313
E-mail: aacr@aol.com

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AACR Board of Directors. Dues for 1995 and 1996 have been set at $35 per year for residents of the Americas and $45 for residents of other countries. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in November 1995 for the forthcoming annual meeting must have paid dues for 1995. Any newly elected associate members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member’s subscription.

Each Fall the AACR will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member’s current registrar, dean, or department head, verifying the member’s current academic status. The Association’s By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1995 may retain associate membership until December 31, 1999. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti, Ph.D.
Executive Director
APPLICATION FOR ASSOCIATE MEMBERSHIP

NAME OF CANDIDATE: ___________________________ DATE OF BIRTH: __________

LAST FIRST M.I.

INSTITUTIONAL AFFILIATION: ______________________________________________________

INSTITUTIONAL ADDRESS: ________________________________________________________

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER: ________________________ FAX NUMBER: ______________________

PRESENT ACADEMIC STATUS/TITLE (Please check only one): ____________________________

_____ Graduate Student  _____ Medical Student

_____ Physician in Training  _____ Postdoctoral Fellow

PRIMARY FIELD OF RESEARCH (Please check only one):

_____ Biochemistry and Biophysics  _____ Biostatistics

_____ Cellular Biology and Genetics  _____ Clinical Investigations

_____ Epidemiology  _____ Immunology

_____ Preclinical Pharmacology and Experimental Therapeutics

Virology  _____ Other: ____________________________ (Please specify)

ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)

__________________________________________________________

__________________________________________________________

__________________________________________________________

RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)

__________________________________________________________

__________________________________________________________

__________________________________________________________

PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on which the candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)

__________________________________________________________

__________________________________________________________

__________________________________________________________

CANDIDATE NOMINATED BY*: ____________________________________________ (Please print)

SIGNATURES

I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are true.

Signature of Candidate: ____________________________________________ Date: __________

I recommend this candidate for associate membership in the American Association for Cancer Research. To the best of my knowledge, the candidate is qualified for this class of membership, and the statements on this application are true.

Signature of Nominator*: ____________________________________________ Date: __________

Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. Enclose a check in U.S. funds, made payable to AACR, Inc., and drawn on a U.S. bank for one year’s dues. Dues are currently $35 for associate members residing in the Americas and $45 for residents of other countries.

Check one of the following boxes only if this form is being submitted between September 1 and December 31:

☐ current  ☐ forthcoming calendar year.

(NOTE: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible to sponsor an abstract for presentation at the annual meeting in March on April of that year.) See Guidelines for Application on the reverse side of this form for further instructions.

*Nominator must be active, corresponding, emeritus, or honorary member of the AACR.

(This form may be reproduced.)
Guidelines for Submitting Disks to American Association for Cancer Research Publications

The word processing packages that we prefer are as follows:

<table>
<thead>
<tr>
<th>MacWrite</th>
<th>WordPerfect (DOS, Windows, and Macintosh)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microsoft Word (DOS, Windows, and Macintosh)</td>
<td>XyWrite (DOS and Windows)</td>
</tr>
</tbody>
</table>

Also acceptable:

<table>
<thead>
<tr>
<th>Ability</th>
<th>Mass 11</th>
<th>SoloWriter</th>
</tr>
</thead>
<tbody>
<tr>
<td>AmiPro</td>
<td>MS Windows Write</td>
<td>Sprint</td>
</tr>
<tr>
<td>A_\text{\textit{TeX}}</td>
<td>MS Works</td>
<td>Stx</td>
</tr>
<tr>
<td>Appleworks</td>
<td>MS Works WP Mac</td>
<td>SunWrite</td>
</tr>
<tr>
<td>ArborTeX</td>
<td>Multimate</td>
<td>Symphony</td>
</tr>
<tr>
<td>ArborText</td>
<td>Multimate Advantage</td>
<td>TEX</td>
</tr>
<tr>
<td>ClarsWorks WP</td>
<td>Nibia</td>
<td>TeX78</td>
</tr>
<tr>
<td>CPT 8000</td>
<td>Nisus (to ASCII file)</td>
<td>Text EXecutive</td>
</tr>
<tr>
<td>CTOS</td>
<td>Notewriter</td>
<td>Textures</td>
</tr>
<tr>
<td>Diablo</td>
<td>Obun</td>
<td>Total Word</td>
</tr>
<tr>
<td>DisplayWrite</td>
<td>OfficeWriter</td>
<td>Troff</td>
</tr>
<tr>
<td>Duet</td>
<td>PC Write</td>
<td>_\text{\textit{TeX}}</td>
</tr>
<tr>
<td>Einstein</td>
<td>PFS First Choice</td>
<td>Volkswriter</td>
</tr>
<tr>
<td>Enable</td>
<td>Professional Write</td>
<td>VuWriter</td>
</tr>
<tr>
<td>EXP</td>
<td>Q&amp;A Write</td>
<td>Wang OIS</td>
</tr>
<tr>
<td>Final Word</td>
<td>Quark XPress</td>
<td>Wang WPS</td>
</tr>
<tr>
<td>FullWrite</td>
<td>RagTime MS Works</td>
<td>Wang Writer</td>
</tr>
<tr>
<td>GemWord Plus</td>
<td>(to ASCII file)</td>
<td>Window Works</td>
</tr>
<tr>
<td>IBM Writing Assistant</td>
<td>Rich Text Format</td>
<td>Windows Write</td>
</tr>
<tr>
<td>Interleaf</td>
<td>RSG (to ASCII file)</td>
<td>WiziWord</td>
</tr>
<tr>
<td>L\text{\textit{aTeX}}</td>
<td>Signature</td>
<td>Wordstar</td>
</tr>
<tr>
<td>Latex</td>
<td>SLITEX</td>
<td>Wordstar 2000</td>
</tr>
<tr>
<td>Leading Edge</td>
<td>SmartWhere</td>
<td>WriteNow</td>
</tr>
<tr>
<td>Lotus Manuscript</td>
<td>SmartWrite II</td>
<td>Xerox</td>
</tr>
<tr>
<td>Lotus Write</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Software packages that we are unable to translate:

<table>
<thead>
<tr>
<th>FrameMaker</th>
<th>Ready, Set, Go</th>
</tr>
</thead>
<tbody>
<tr>
<td>PageMaker</td>
<td>Scientific Writer</td>
</tr>
</tbody>
</table>

Disks produced on IBM or IBM-compatible computers are preferred, but those produced on some Apple or Wang computers can also be converted. Because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK. DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.
DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along with the required four hard copy printouts. Disks will ultimately be returned to the authors.

File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in one file. Mathematical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Please label the outside of the disk with the journal name, the first author’s name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide ALL the information.

Name used to access paper on disk: ________________________________
Name of computer used (e.g., IBM/PS2): ____________________________
Operating system and version (e.g., DOS 3.3): ________________________
Word processing program and version (e.g., WordPerfect 5.0): ________
[See reverse for acceptable programs.]

Manuscript number: _____________________________________________
First author: ____________________________________________________
Corresponding author (if different from first author): _________________
Telephone/FAX numbers: _________________________________________

This form (both sides) may be reproduced.
AMERICAN ASSOCIATION FOR CANCER RESEARCH
SCIENTIFIC CONFERENCES

OCTOBER 2-6, 1996
**Novel Approaches in Blood and Marrow Transplantation**
Second Annual Meeting of the American Society for Blood and Marrow Transplantation
Chairpersons: O. Michael Colvin, Durham, NC; Bruce R. Blazar, Minneapolis, MN
Hotel Del Coronado, San Diego, CA

OCTOBER 6-9, 1996
**Carcinogenesis from Environmental Pollution: Assessment of Human Risks and Strategies for Prevention**
Joint Meeting with International Agency for Research on Cancer
Chairpersons: Frederica Perera, New York, NY; Paul Kleihues, Lyon, France
Hotel Gellért, Budapest, Hungary

OCTOBER 19-23, 1996
**Programmed Cell Death**
Chairpersons: Stanley J. Korsmeyer, St. Louis, MO; Shigekazu Nagata, Osaka, Japan; Andrew Wylie, Edinburgh, Scotland
The Sagamore, Bolton Landing (Lake George), NY

JANUARY 10-14, 1997
**Basic and Clinical Aspects of Lymphoma**
Joint Meeting with the American Society of Clinical Oncology
Chairpersons: Joseph R. Bertino, New York, NY; James O. Armitage, Omaha, NE
Stouffer Renaissance Esmeralda Resort, Indian Wells (Palm Springs), CA

JANUARY 17-21, 1997
**Disrupted Transcription Factors in Cancer**
Chairpersons: Peter K. Vogt, La Jolla, CA; Frank J. Rauscher III, Philadelphia, PA
Hotel Del Coronado, San Diego, CA

FEBRUARY 13-16, 1997
**Growth Factors, Signaling, and Cancer**
Joint Meeting with Lorne Cancer Conference
Chairpersons: Antony Burgess, Parkville, Victoria, Australia; Robert J. Coffey, Nashville, TN; Ashley R. Dunn, Parkville, Victoria, Australia; Webster K. Cavenee, La Jolla, CA
Erskine House, Lorne, Victoria, Australia

FEBRUARY 23-28, 1997
**Cell Signaling and Cancer Treatment**
In Collaboration with British Association for Cancer Research, Austrian Cancer Society, German Cancer Society, and Austrian Biochemical Society
Chairpersons: Hans H. Grunicke, Innsbruck, Austria; Garth Powis, Tucson, AZ; Paul Workman, Macclesfield, England
Interalpen-Hotel Tyrol, Telfs-Buchen, Austria

MARCH 7-12, 1997
**Basic and Clinical Aspects of Breast Cancer**
Chairpersons: J. Carl Barrett, Research Triangle Park, NC; Karen S.H. Antman, New York, NY; Mary-Claire King, Seattle, WA
Keystone Resort, Keystone, CO

APRIL 12-16, 1997
**88th Annual Meeting**
Chairperson: Frederick P. Li, Boston, MA
Co-Chairpersons: Clara Derber Bloomfield, Buffalo, NY; Stephen H. Friend, Seattle, WA
San Diego Convention Center, San Diego, CA
Abstract Deadline: November 12, 1996

JUNE 7-12, 1997
**Cancer of the Central Nervous System**
Conference with Neurosurgery Joint Section on Tumors
Chairpersons: Peter McL. Black, Boston, MA; Webster K. Cavenee, La Jolla, CA
Loew's Coronado Bay Resort, San Diego, CA

AACR members will receive brochures on the above conferences as soon as they are available. Nonmembers should call or write:
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 • 215-440-9313 (FAX)
E-Mail: aacr@aol.com

For regular updates to this list visit the AACR's World Wide Web site, http://www.aacr.org
AACR/ASCO JOINT CONFERENCE

Basic and Clinical Aspects of Lymphoma

January 10-14, 1997
Renaissance Esmeralda Resort
Indian Wells (Palm Springs), CA

CONFERENCE CO-CHAIRPERSONS

James O. Armitage / Omaha, NE
Joseph R. Bertino / New York, NY

PROGRAM COMMITTEE

Franco G. Cavalli / Bellinzona, Switzerland
Raju S. K. Chaganti / New York, NY
Thomas M. Grogan / Tucson, AZ
Alexandra M. Levine / Los Angeles, CA

Bruce A. Chabner / Boston, MA
Richard I. Fisher / Maywood, IL
Ronald Levy / Stanford, CA
Sharon B. Murphy / Chicago, IL

CONFERENCE PROGRAM

Keynote Address
Saul A. Rosenberg / Stanford, CA

Can We Improve Outcome with Available Therapies?
Sharon B. Murphy / Chicago, IL
Joseph R. Bertino / New York, NY
John H. Glick / Philadelphia, PA

The New Entities and Classification
Richard I. Fisher / Maywood, IL
Dennis D. Weisenburger / Omaha, NE
James O. Armitage / Omaha, NE

New Therapies
Bruce A. Chabner / Boston, MA
Ronald Levy / Stanford, CA
Oliver W. Press / Seattle, WA

Lymphomagenesis and Etiology
Franco G. Cavalli / Bellinzona, Switzerland

Additional Speakers to be Announced

Genetic Abnormalities in Lymphoma
Raju S. K. Chaganti / New York, NY
Riccardo Dalla-Favera / New York, NY
Stephan W. Morris / Memphis, TN
Diane C. Louie / New York, NY

Applicants are encouraged to submit abstracts for oral and poster presentation.

Cell Adhesion and Cell Signaling/
Molecular and Homing Receptors
Thomas M. Grogan / Tucson, AZ
Douglas R. Green / San Diego, CA

Application Deadline: November 1, 1996

Information and Application Forms:
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
World Wide Web: http://www.aacr.org
Novel Approaches in Blood and Marrow Transplantation

October 2-6, 1996
Hotel del Coronado
San Diego, CA

Co-Sponsored by the College of Physicians & Surgeons of Columbia University

ASBMT and AACR gratefully acknowledge Sandoz Oncology and SyStemix, Inc.,
who have provided generous unrestricted educational grants for this meeting.

CONFERENCE CO-CHAIRPERSONS
Bruce R. Blazar / Minneapolis, MN  O. Michael Colvin / Durham, NC

PROGRAM COMMITTEE
Karen S. H. Antman / New York, NY  Olivera J. Finn / Pittsburgh, PA
Joseph R. Bertino / New York, NY  Ronald E. Gress / Bethesda, MD
Barbara E. Bierer / Boston, MA  Helen E. Heslop / Memphis, TN
Richard E. Champlin / Houston, TX  John H. Kersey / Minneapolis, MN
Nelson J. Chao / Stanford, CA  Keith M. Sullivan / Seattle, WA
Connie J. Eaves / Vancouver, BC, Canada

PLENARY SESSIONS
Pharmacologic Approaches to Reducing Malignancy
Joseph R. Bertino / New York, NY
Robert B. Diasio / Birmingham, AL
William Hryniuk / San Diego, CA
O. Michael Colvin / Durham, NC

Biologic Approaches to Reducing Malignancy
Martin Kast / Chicago, IL
Fatih M. Uckun / Minneapolis, MN
John R. Murphy / Boston, MA
Glenn Dranoff / Boston, MA

Options for Hematopoietic Progenitor Cell Sources
Christopher Juttner / Palo Alto, CA
Peter M. Lansdorp / Vancouver, BC, Canada
Jan Nolta / Los Angeles, CA
Paul Martin / Seattle, WA

Allogeneic Approaches to Reducing Malignancy Post-BMT
Bruce R. Blazar / Minneapolis, MN
Ronald E. Gress / Bethesda, MD
Robert Kornfeld / Philadelphia, PA
Lee M. Nadler / Boston, MA

Biology of Breast Cancer
Mien Chie Hung / Houston, TX
Karen S. H. Antman / New York, NY
Jeffrey T. Holt / Nashville, TN
Daniel D. Von Hoff / San Antonio, TX

Policy Issues
Joseph W. Fay / Dallas, TX
Scott D. Rowley / Seattle, WA
Elizabeth J. Shpall / Denver, CO
Richard E. Champlin / Houston, TX

SCIENTIFIC SUBCOMMITTEES AND CHAIRPERSONS
Solid Tumors
Emil Frei III / Boston, MA
William P. Peters / Detroit, MI

Lymphoid Malignancies
Jerome Ritz / Boston, MA
Gordon L. Phillips / Lexington, KY

Experimental Therapeutics
O. Michael Colvin / Durham, NC
Stanley Riddell / Seattle, WA

Gene Therapy
Donald B. Kohn / Los Angeles, CA
Malcolm K. Brenner / Memphis, TN

Growth Factors and Sources of Stem Cells
Joanne Kurtzberg / Durham, NC
Malcolm A. S. Moore / New York, NY

Graft Rejection/GVHD/GVL
Robert B. Levy / Miami, FL
Martin A. Cheever / Seattle, WA

Supportive Care
John R. Wingard / Atlanta, GA
Raleigh Bowden / Seattle, WA

Leukemias
Edward D. Ball / Pittsburgh, PA
Michael L. Cleary / Stanford, CA

Non-malignant Disorders:
Congenital and Acquired
Robertson M. Parkman / Los Angeles, CA
Rainer F. Storb / Seattle, WA

WORKSHOP TITLES AND CHAIRPERSONS
Tumor Biology and Residual Disease Detection
Paul M. Sondel / Madison, WI
John Gribben / Boston, MA

Information and Registration Forms:
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 / 215-440-9313 (FAX)
e-mail: aacr@aol.com
PLENARY SESSION
Genetic Predisposition to Cancer (Louise C. Strong)

SYMPOSIA
Genes, Cell Proliferation, and Antineoplastic Drugs (George F. Vande Woude)

Diagnostic, Prognostic, and Therapeutic Aspects of Tumor Suppressor Genes (David Sidransky)

Cell Cycle Regulation

Breast Cancer Genes

Metastasis, Adhesion, and Angiogenesis: Mechanisms and Therapeutic Strategies (Marilyn M. Cornwell)

Novel Clinical Trials Based on Genetics and Molecular Therapeutics (Stephen H. Friend)

Apoptosis and Cancer Chemotherapy (Michael B. Kastan)

Identification and Management of Genetic-High-Risk Individuals (Albert de la Chapelle)

Demistifying the Role of Cytokines in Tumor Immunobiology: Status and Future Utility (Michael A. Caligiuri)

Telomerase and Clinical Applications (Titia de Lange)

Acute Myelocytic Leukemia (Clara Derber Bloomfield)

Prostate Cancer

Colon Cancer (Margaret A. Tempero)

Signaling Pathways for Novel Therapeutics (Anthony J. Pawson)

Animal Models for Functional Analysis of Tumor Suppressor Genes

New Techniques for Molecular Diagnostics

Mechanisms of Cellular Senescence (J. Carl Barrett)

Damage Response Pathways (Philip C. Hanawalt)

Gene Interactions with the Environment/ Carcinogenesis (Allan Balmain)

Epidemiology and Pathogenesis of Secondary Cancers (Frederick P. Li)

METHODS WORKSHOPS, EDUCATIONAL, CONTROVERSY, AND MEET-THE-EXPERT SUNRISE SESSIONS
To be announced

Abstract Deadline: November 12, 1996

Further Information: AACR Office • Public Ledger Building • Suite 816 • 150 S. Independence Mall West Philadelphia, PA 19106-3483 • TELEPHONE: (215) 440-9300 • FAX: (215) 440-9313 • Email: aacr@aol.com

For up-to-date information visit the AACR web site at http://www.aacr.org